Effect of Avastin in Juxtafoveal Telangiectasias

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was  Recruiting
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
First received: November 30, 2006
Last updated: December 1, 2006
Last verified: November 2006
Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias

Condition Intervention Phase
Drug: Bevacizumab
Procedure: Intravitreal injection of Bevacizumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Does Avastin Change Evolution in Juxtafoveal Telangiectasias?

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Best corrected Visual Acuity
  • Fluorescein Angiogram: Leakage
  • Optical Coherence Tomography: Retinal thickness

Study Start Date: September 2006
Estimated Study Completion Date: November 2006
Detailed Description:
After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT.

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion
  • Patients with Idiopathic Juxtafoveal Retinal Telangiectasias

Exclusion Criteria:

  • Diabetic Retinopathy and Diabetic Macular Edema
  • Hypertensive Retinopathy
  • Choroidal Neovascularization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00406380

Contact: Verónica Kon-Jara, MD 5510841400 ext 1171-1172 veronicakon@yahoo.com
Contact: Orlando Ustariz-Gonzalez, MD 5510841400 ext 1171-1172

Asociacion para Evitar la Ceguera en Mexico Recruiting
Mexico, DF, Mexico, 04030
Contact: Veronica Kon-Jara, MD    5510841400 ext 1171-1172    veronicakon@yahoo.com   
Sub-Investigator: Orlando Ustariz-Gonzalez, MD         
Sub-Investigator: Elizabeth Reyna-Castelan, MD         
Sub-Investigator: Nelida Salazar-Teran, MD         
Sub-Investigator: Jans Fromow-Guerra, MD         
Sub-Investigator: Hugo Quiroz-Mercado, MD         
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Veronica Kon-Jara, MD Asociación para Evitar la Ceguera en México
  More Information

ClinicalTrials.gov Identifier: NCT00406380     History of Changes
Other Study ID Numbers: APEC-0024 
Study First Received: November 30, 2006
Last Updated: December 1, 2006
Health Authority: Mexico: National Institute of Public Health, Health Secretariat

Keywords provided by Asociación para Evitar la Ceguera en México:
Telangiectasias secondary to Branch Retinal Vein Occlusion (BRVO)
Idiopathic juxtafoveal retinal telangiectasias

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016